Runny Nose After Mounjaro (Tirzepatide)
A runny nose is not a recognized or documented side effect of tirzepatide (Mounjaro) based on FDA labeling and clinical trial data, and should prompt evaluation for alternative causes such as concurrent upper respiratory infection, allergies, or unrelated conditions.
What the Evidence Shows
The FDA-approved prescribing information for Mounjaro lists comprehensive adverse effects, and rhinorrhea (runny nose) is notably absent from both common and serious side effects 1. The documented side effects are predominantly:
- Gastrointestinal: nausea, diarrhea, vomiting, constipation, indigestion, abdominal pain (most common, affecting up to 25% for nausea) 2, 1
- Injection site reactions: pain at injection site 3
- Metabolic: decreased appetite, blood glucose fluctuations 3
- Serious but rare: pancreatitis, gallbladder disease, kidney problems, allergic reactions 1
Real-World Safety Data
A comprehensive 2025 analysis of FDA Adverse Event Reporting System (FAERS) data covering 65,974 reports from 2022-2025 identified the most common adverse events with tirzepatide 3. Upper respiratory tract infection was mentioned in clinical trials 2, but this represents an infectious process, not a drug-induced runny nose.
The real-world safety profile confirms:
- Dosing errors (most reported)
- Injection-site reactions
- Gastrointestinal issues
- No signal for rhinorrhea as a drug effect 3
Clinical Approach
Evaluate for alternative causes:
- Concurrent viral upper respiratory infection - the most likely explanation, as these are common and coincidental timing with medication initiation is frequent
- Allergic rhinitis - seasonal or environmental triggers unrelated to tirzepatide
- Vasomotor rhinitis - non-allergic causes
- Medication excipients - while tirzepatide contains only sodium chloride, sodium phosphate, and water for injection 1, true allergic reactions would present with more serious symptoms (facial swelling, breathing difficulty, rash) 1
Management Recommendation
Continue tirzepatide unless other concerning symptoms develop. The runny nose should be managed as you would any upper respiratory symptom in a patient not on this medication:
- Symptomatic treatment with antihistamines or decongestants as appropriate
- Monitor for progression to serious allergic reaction symptoms (facial swelling, difficulty breathing, severe rash) which would require immediate discontinuation 1
- If symptoms persist beyond typical viral illness duration (7-10 days), evaluate for other rhinitis causes
Important Caveat
Do not attribute every symptom to a new medication. The timing of symptom onset relative to medication initiation does not establish causation. The extensive clinical trial program (SURPASS trials) and post-marketing surveillance have not identified rhinorrhea as a tirzepatide-related adverse effect 4, 5, 6.